Cystic Fibrosis (CF) Therapeutics Market Report 2026

Cystic Fibrosis (CF) Therapeutics Market Overview

• Cystic Fibrosis (CF) Therapeutics market size has reached to $8.34 billion in 2025 • Expected to grow to $11.72 billion in 2030 at a compound annual growth rate (CAGR) of 7.1% • Growth Driver: Growing Patient Numbers Drive Momentum in Cystic Fibrosis Therapeutics Market • Market Trend: Fibrosis Innovation Hub Network To Accelerate CF Treatment Development • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Cystic Fibrosis (CF) Therapeutics Market?

Cystic fibrosis (CF) therapeutics refers to medications that thin and facilitate coughing up lung mucus. It is an inherited disorder that causes severe damage to the lungs, digestive system, and other organs in the body. The main drug classes for cystic fibrosis (CF) therapeutics are pancreatic enzyme supplements, mucolytics, bronchodilators and CFTR modulators. Pancreatic enzyme supplements refer to supplements produced by the pancreas and containing pancreatin or pancrelipase, which is a combination of lipase, amylase, and protease. There are two routes of administration such as oral and inhaled. It includes methods of cystic fibrosis treatment with medication and devices.

What Is The Cystic Fibrosis (CF) Therapeutics Market Growth Forecast?

The cystic fibrosis (cf) therapeutics market size is expected to see strong growth in the next few years. It will grow to $11.72 billion in 2030 at a compound annual growth rate (CAGR) of 7.1%. The growth in the forecast period can be attributed to advancements in gene therapy, increased adoption of digital health solutions, rise in precision medicine applications, expansion of pediatric cf treatment programs, growing investment in rare disease therapeutics. Major trends in the forecast period include personalized cystic fibrosis therapies, advanced pulmonary drug delivery systems, gene editing & cftr gene therapy research, patient adherence & remote monitoring solutions, orphan drug development for rare cf mutations.

Global Cystic Fibrosis (CF) Therapeutics Market Segmentation

1) By Drug Class: Pancreatic Enzyme Supplements, Mucolytic, Bronchodilators, CFTR Modulators 2) By Route Of Administration: Oral, Inhaled 3) By Treatment Method: Medication, Devices Subsegments: 1) By Pancreatic Enzyme Supplements: Lipase, Amylase, Protease 2) By Mucolytics: Dornase Alfa (Pulmozyme), Hypertonic Saline 3) By Bronchodilators: Short-Acting Beta Agonists (SABAs), Long-Acting Beta Agonists (LABAs), Anticholinergics 4) By CFTR Modulators: Ivacaftor, Lumacaftor Or Ivacaftor (Orkambi), Tezacaftor Or Ivacaftor (Symdeko), Elexacaftor Or Tezacaftor Or Ivacaftor

What Is The Driver Of The Cystic Fibrosis (CF) Therapeutics Market?

An increase in the number of patients suffering from cystic fibrosis is expected to propel the growth of the cystic fibrosis (CF) therapeutics market going forward. Cystic fibrosis (CF) is an inherited condition that severely harms the body's lungs, digestive system, and other organs. Cystic fibrosis therapeutics are used to treat cystic fibrosis disorder by making the mucus in the lungs thinner and easier to cough up. Thus, an increase in the number of patients suffering from cystic fibrosis is expected to boost the cystic fibrosis (CF) therapeutics market. For instance, in 2023, according to the Cystic Fibrosis Foundation, a U.S.-based nonprofit, non-governmental organization (NGO), there were 32,547 individuals in the CF Patient Registry in 2022 compared to 33,288 in 2023, representing a growth of nearly 2.3%. Therefore, an increase in the number of patients suffering from cystic fibrosis is driving the growth of the cystic fibrosis (CF) therapeutics industry.

Key Players In The Global Cystic Fibrosis (CF) Therapeutics Market

Major companies operating in the cystic fibrosis (cf) therapeutics market are Teva Pharmaceutical Industries Ltd., F. Hoffmann-La Roche AG, Vertex Pharmaceuticals Incorporated, Chiesi Farmaceutici SpA, PTC Therapeutics LIMITED, Genentech Inc., Alaxia, AstraZeneca, Beyond Air Inc., Pfizer Inc., Alcresta Therapeutics Inc., Laurent Pharmaceuticals, Nestlé HealthScience, Pharmaxis, Bayer AG, AbbVie Inc., Novartis AG, Arcturus Therapeutics Holdings Inc., Arrowhead Pharmaceuticals Inc, ProQR Therapeutics N.V., Enterprise Therapeutics Ltd. , Corbus Pharmaceuticals Holdings Inc, Eloxx Pharmaceuticals , Translate Bio Inc, Zambon S.p.A

Global Cystic Fibrosis (CF) Therapeutics Market Trends and Insights

Major companies operating in the cystic fibrosis (CF) therapeutics market are innovating treatment and patient care solutions, such as the cystic fibrosis innovation hub network, to accelerate research, improve treatment options, and enhance collaboration in the development of new therapies for CF patients. The cystic fibrosis innovation hub network is a collaborative platform or initiative designed to accelerate the research and development of new treatments for cystic fibrosis (CF). For instance, in October 2024, LifeArc, a UK-based charity and life sciences company that focuses on translating scientific research into viable healthcare solutions, launched the UK’s first Cystic Fibrosis Innovation Hub Network. Cystic Fibrosis Innovation Hub Network is designed to enhance research and development for cystic fibrosis (CF) treatments, fostering collaboration between healthcare providers, researchers, and patients. Launched as part of a broader initiative to accelerate innovation in cystic fibrosis therapies, the hub focuses on identifying new pathways for drug development and improving patient outcomes.

What Are Latest Mergers And Acquisitions In The Cystic Fibrosis (CF) Therapeutics Market?

In July 2024, Sionna Therapeutics, a US-based healthcare organization acquired rights to develop and commercialize multiple cystic fibrosis (CF) compounds from AbbVie inc, for an undisclosed amount. With this acquisition, Sionna commercializes three specific compounds such as ABBV-2222, ABBV-3067, and ABBV-2851 to improve efficiency for cystic fibrosis (CF) treatment. AbbVie Inc. is a US-based company that provides cystic fibrosis (CF) therapeutics.

Regional Insights

North America was the largest region in the cystic fibrosis (CF) therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the cystic fibrosis (CF) therapeutics market during the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Cystic Fibrosis (CF) Therapeutics Market?

The cystic fibrosis (CF) therapeutics market includes revenues earned by entities by providing services that include administration of mucus thinner, airway clearance, and antibiotics. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Cystic Fibrosis (CF) Therapeutics Market Report 2026?

The cystic fibrosis (cf) therapeutics market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the cystic fibrosis (cf) therapeutics industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.